Nanowired delivery of drugs and antibodies for neuroprotection in brain diseases with co-morbidity factors. Part B /
Clasificación: | Libro Electrónico |
---|---|
Otros Autores: | , , |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
San Diego :
Elsevier Science & Technology,
2023.
|
Edición: | 1st ed. |
Colección: | International review of neurobiology ;
v. 172 |
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- References
- Acknowledgements
- Section 1 Spinal cord Injury
- Chapter One: Spinal cord injury induced exacerbation of Alzheimer's disease like pathophysiology is reduced by topical application of nanowired cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and tumor necrosis factor alpha
- Abstract
- 1 Introduction
- 2 Spinal cord injury and Alzheimer's disease
- 3 Our observation on spinal cord injury and Alzheimer's disease pathology
- 4 Spinal cord injury and blood-spinal cord barrier
- 5 Possible mechanism of neuroprotection in spinal cord injury
- 6 Conclusion and future perspectives
- References
- Chapter Two: Nanodelivery of histamine H3 receptor inverse agonist BF-2649 with H3 receptor antagonist and H4 receptor agonist clobenpropit induced neuroprotection is potentiated by antioxidant compound H-290/51 in spinal cord injury
- Abstract
- 1 Introduction
- 2 Nanowired delivery of H-290/51 with histaminergic H3 and H4 receptor modulators in spinal cord injury
- 3 Our observations in spinal cord injury
- 4 Blood-spinal cord barrier in spinal cord injury
- 5 Spinal cord edema and volume swelling in spinal cord injury
- 6 Spinal cord blood flow in spinal cord injury
- 7 Oxidative stress parameters in spinal cord injury
- 8 Neuropathology of spinal cord injury
- 9 Molecular markers of neuropathology in spinal cord injury
- 10 Possible mechanisms of neuroprotection in spinal cord injury
- Acknowledgments
- References
- Chapter Three: Neuromodulation and quality of life for patient with spasticity after spinal cord injury
- Abstract
- 1 Introduction
- 2 Materials and methods
- 3 Results
- 4 Discussion
- References
- Section 2 Neurodegenerative disease.
- Chapter Four: Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment
- Abstract
- 1 Introduction
- 2 Nanoparticle-drug delivery systems in PD therapeutics
- 3 Enriched environment as non-invasive strategy for PD treatment
- 4 Synergistic effect of an enriched environment and nanodelivery administration
- 5 Concluding remarks
- References
- Chapter Five: Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with mild traumatic brain injury
- Abstract
- 1 Introduction
- 2 Methodological consideration
- 3 Our observations on nanowired DL-3-n-butylphthalide in Alzheimer's disease
- 4 Possible mechanisms of DL-3-n-butylphthalide in neuroprotection in Alzheimer's disease
- Acknowledgments
- References
- Section 3 Drugs of abuse and neurotoxicity
- Chapter Six: Nicotine neurotoxicity exacerbation following engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron
- Abstract
- 1 Introduction
- 2 Our observations on metal nanoparticles exposure and nicotine neurotoxicity
- 3 Observations on nicotine neurotoxicity with nanoparticles exposure
- 4 Molecular markers of neuroinflammation
- 5 Molecular markers of oxidative stress
- 6 Possible mechanisms of neuroprotection in nicotine neurotoxicity
- Acknowledgments
- References
- Section 4 Clinical neurology and oncology
- Chapter Seven: Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention
- Abstract
- 1 Introduction
- 2 Description of the proposed technology.